Refine by
Drug Effectiveness Reporting And Monitoring Articles & Analysis
17 news found
Creative BioMart, one of the world leading biotechnology companies serving science, recently updated its R-PEAPC Conjugated Proteins offerings to meet different research needs and applications. R-PE Labeled Proteins are labeled products generated by combining R-PE fluorescent dyes with proteins. R-PE labeled protein is non-toxic, odorless, and has high stability. And when the excitation ...
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing. Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary ...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in achieving the proteinuria ...
“We’re thrilled to build out the body of data that reinforces voclosporin as a safe and effective treatment option for lupus nephritis patients over the long ...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of ...
Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 2022 National Kidney Foundation Spring Clinical Meetings, taking place April 6-10, 2022 in Boston, Mass. ...
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy - Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroids alone, the active study control - Similar to the active control, the voclosporin-treated group maintained stable ...
Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 – Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compared with placebo - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with stable eGFR at 30 ...
Manassas, VA (October 12, 2021) - Notal Vision, Inc. reported today that results of the first U.S.-based feasibility study with its investigational home-based optical coherence tomography (OCT) platform were presented at the Retina Society and the American Society of Retina Specialists (ASRS) annual meetings. The Notal Home OCT pipeline technology is designed to provide patient-initiated retinal ...
Salvatore J. Salamone, Ph.D. received the prestigious Dr. C.E. Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that ...
MOBILion Systems Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. The round was led by D1 Capital Partners with the remaining funds contributed by existing investors aMoon, Agilent Technologies (NYSE:A), IP Group, Hostplus and ...
MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides fast, efficient separations with superior resolution and reproducibility, faster, simpler method development, and greater instrument ...
Led by King's College London and also involving the University of Hertfordshire, the Inhalation Translation Challenge aims to help reduce the number of animals used to test medicines for treating inflammatory diseases of the airways such as asthma. Following a successful proof-of-concept study (Phase 1) and a 'Dragons' Den' style interview process, the project was the winning team chosen to ...
West Wireless Health Institute (WWHI) today announced a collaboration with GE Healthcare, a global leader in health care technology, on a variety of research, technology and educational initiatives focused on accelerating wireless health solutions. GE Healthcare has demonstrated innovative leadership in the emerging wireless health industry. WWHI is forging technology and educational partnerships ...